YMAB250117P2500
- 0.00
- 0.000.00%
Y-mAbs Therapeutics Newsroom
BofA Securities Maintains Y-mAbs Therapeutics(YMAB.US) With Hold Rating, Maintains Target Price $14
JonesTrading Maintains Y-mAbs Therapeutics(YMAB.US) With Buy Rating, Maintains Target Price $23
JonesTrading Sticks to Their Buy Rating for Y-Mabs Therapeutics (YMAB)
BofA Securities Maintains Y-mAbs Therapeutics(YMAB.US) With Hold Rating, Cuts Target Price to $14
JonesTrading Maintains Y-mAbs Therapeutics(YMAB.US) With Buy Rating, Maintains Target Price $23
Y-mAbs Therapeutics Analyst Ratings
H.C. Wainwright Maintains Y-mAbs Therapeutics(YMAB.US) With Buy Rating, Maintains Target Price $22
Promising Preclinical Data on CD38-SADA Justifies Buy Rating for Y-Mabs Therapeutics
CCORF Maintains Y-mAbs Therapeutics(YMAB.US) With Buy Rating, Maintains Target Price $26
Brookline Capital Initiates Y-mAbs Therapeutics(YMAB.US) With Buy Rating, Announces Target Price $17
Y-mAbs Therapeutics Price Target Announced at $17.00/Share by Brookline Capital
Y-mAbs Therapeutics Initiated at Buy by Brookline Capital
Oppenheimer Initiates Y-mAbs Therapeutics(YMAB.US) With Buy Rating, Announces Target Price $23
Oppenheimer Initiates Coverage On Y-mAbs Therapeutics With Outperform Rating, Announces Price Target of $23
Y-mAbs Therapeutics Analyst Ratings
H.C. Wainwright Maintains Y-mAbs Therapeutics(YMAB.US) With Buy Rating, Maintains Target Price $22
JonesTrading Maintains Y-mAbs Therapeutics(YMAB.US) With Buy Rating, Maintains Target Price $23
Morgan Stanley Maintains Y-mAbs Therapeutics(YMAB.US) With Sell Rating, Maintains Target Price $11
Truist Financial Maintains Y-mAbs Therapeutics(YMAB.US) With Buy Rating, Announces Target Price $21
Truist Financial Remains a Buy on Y-Mabs Therapeutics (YMAB)